TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
-9.93%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$224M
AUM Growth
+$224M
(+2.2%)
Cap. Flow
+$29.3M
Cap. Flow
% of AUM
13.04%
Top 10 Holdings %
Top 10 Hldgs %
99.56%
Holding
15
New
–
Increased
4
Reduced
–
Closed
3
Top Buys
| 1 |
RXDX
Ignyta, Inc.
RXDX
|
$21.3M |
| 2 |
Heron Therapeutics
HRTX
|
$18.2M |
| 3 |
Lipocine
LPCN
|
$486K |
| 4 |
ATYR
aTyr Pharma
ATYR
|
$249K |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$4.88M |
| 2 |
Opko Health
OPK
|
$3.64M |
| 3 |
INFI
Infinity Pharmaceuticals, Inc.
INFI
|
$2.42M |
Sector Composition
| 1 | Healthcare | 87.31% |
| 2 | Consumer Discretionary | 2.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Heron Therapeutics
HRTX
$207M
| $112M | 49.84% | 6,197,198 +1,006,361 | +19% | +$18.2M |
|
|
LJPC
2
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $48.8M | 21.76% | 3,052,130 | – | – |
|
|
RXDX
3
DELISTED
Ignyta, Inc.
RXDX
| $21.5M | 9.59% | 3,972,800 +3,932,800 | +9,832% | +$21.3M |
|
4
BioMarin Pharmaceuticals
BMRN
$11.2B
| $7.02M | 3.13% | 90,215 | – | – |
|
5
Alibaba
BABA
$322B
| $4.77M | 2.13% | 60,000 | – | – |
|
6
Nektar Therapeutics
NKTR
$568M
| $3.7M | 1.65% | 260,000 | – | – |
|
7
BioCryst Pharmaceuticals
BCRX
$1.74B
| $1.22M | 0.54% | 430,000 | – | – |
|
|
8
Lipocine
LPCN
$15.8M
| $790K | 0.35% | 260,000 +160,000 | +160% | +$486K |
|
|
ATYR
9
aTyr Pharma
ATYR
$527M
| $777K | 0.35% | 279,425 +89,425 | +47% | +$249K |
|
10
Celldex Therapeutics
CLDX
$1.47B
| $220K | 0.1% | 50,000 | – | – |
|
|
11
Opko Health
OPK
$1.1B
| – | – | -350,000 | Closed | -$3.64M |
|
|
INFI
12
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| – | – | -460,000 | Closed | -$2.42M |
|
|
13
Sarepta Therapeutics
SRPT
$1.78B
| – | – | -250,000 | Closed | -$4.88M |
|